Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, November 12, 2012
Sun, November 11, 2012
Fri, November 9, 2012 TranS1 Inc (NASDAQ:TSON), Down By 6.45% ($0.18) From $2.790 After BUYINS.NET Report Predicted Weakness After Earnings
November 9, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Wednesday, November 7th 2012 stating that TranS1 Inc (NASDAQ:TSON) was expected to be Down After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=tson&id=325710
At the time this story was written, TranS1 Inc (NASDAQ:TSON) is Down By 6.45% ($0.18) From $2.790 since the BUYINS.NET report was released.
The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php
TranS1 Inc (NASDAQ:TSON) - TranS1 Inc., a medical device company, focuses on the design, development, and marketing of products that implement its proprietary surgical approach to treat degenerative disc disease and instability affecting the lower lumbar region of the spine. The company offers TranS1 pre-sacral approach that enables spine surgeons to access and treat degenerative lumbar discs, as well as to perform fusion and motion preserving surgeries in the L4/L5/S1 region. Its products include AxiaLIF lumbar fusion implant, a threaded titanium rod to enable one-level L5/S1 fusions and two-level L4/L5/S1 fusions; AxiaLIF 360 implants, which consist of 3D Axial Rod plus its titanium facet screws for supplemental posterior fixation; and TranS1 access and disc preparation instruments. In addition, the company, through a partnership agreement with Life Spine, Inc., distributes Avatar, a minimally invasive pedicle screw system. It markets and sells its products through direct sales representatives and independent sales agents in the United States, as well as primarily through third-party distributors in Europe. The company was formerly known as aXiaMed, Inc. and changed its name to TranS1 Inc. in February 2003. TranS1 Inc. was founded in 2000 and is headquartered in Wilmington, North Carolina..
About BUYINS.NET
BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.
INVESTMENTS & TRADING
SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.
GATS -- tracks and quantifies known trading strategies.
DISCLAIMER:
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. TranS1 Inc (NASDAQ:TSON) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.
Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net
- WOPRAI
- support@woprai.com